Journal for ImmunoTherapy of Cancer (Nov 2023)
769 Interim clinical and translational data from NTC-001, a phase I study to evaluate the non-engineered neoantigen-specific T cell product BNT221 in patients with advanced or metastatic melanoma
- Matthijs D Linssen,
- Divya Lenkala,
- Brian McCarthy,
- Cynthia Nijenhuis,
- Kristen Balogh,
- Mark DeMario,
- Emily Jackson,
- Jessica SW Borgers,
- Victoria Kohler,
- Sebastian Hymson,
- Katya Esaulova,
- Joong Hyuk F Sheen,
- Olivia Finney,
- Sebastian Klobuch,
- Richard B Gaynor,
- John B Haanen,
- Marit MVan Buuren
Affiliations
- Matthijs D Linssen
- 3 Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
- Divya Lenkala
- 1BioNTech US Inc., Cambridge, MA, USA
- Brian McCarthy
- 1BioNTech US Inc., Cambridge, MA, USA
- Cynthia Nijenhuis
- 2Netherlands Cancer Institute, Cambridge, MA, USA
- Kristen Balogh
- 5BioNTech US, Cambridge, MA, USA
- Mark DeMario
- 2BioNTech US, Cambridge, MA, USA
- Emily Jackson
- 2BioNTech US, Cambridge, MA, USA
- Jessica SW Borgers
- 1Netherlands Cancer Institute, Amsterdam, Netherlands
- Victoria Kohler
- 2BioNTech US, Cambridge, MA, USA
- Sebastian Hymson
- 2BioNTech US, Cambridge, MA, USA
- Katya Esaulova
- 2BioNTech US, Cambridge, MA, USA
- Joong Hyuk F Sheen
- 2BioNTech US, Cambridge, MA, USA
- Olivia Finney
- 2BioNTech US, Cambridge, MA, USA
- Sebastian Klobuch
- 1Netherlands Cancer Institute, Amsterdam, Netherlands
- Richard B Gaynor
- 2BioNTech US, Cambridge, MA, USA
- John B Haanen
- 1Netherlands Cancer Institute, Amsterdam, Netherlands
- Marit MVan Buuren
- 2BioNTech US, Cambridge, MA, USA
- DOI
- https://doi.org/10.1136/jitc-2023-SITC2023.0769
- Journal volume & issue
-
Vol. 11,
no. Suppl 1
Abstract
No abstracts available.
